Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Profound Medical Corp.NASDAQ: PROF
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows, but more slowly than its trailing trend
Q1 FY2026 free cash flow of $8.58M (cash outflow) rose 3.6% year over year, behind the +44.5% change in trailing-twelve-month free cash flow. Sequentially, it rose 25.5% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.
Context
- Free cash flow amounted to 238.4% of revenue in FY2025, up 7.8 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +3.6% toward the trailing-twelve-month pace of +44.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (39.05M) USD
- Year-over-year change
- -66.5%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.05M) | -66.5% |
| FY2024 | 2024-12-31 | (23.45M) | -3.7% |
| FY2023 | 2023-12-31 | (22.61M) | +12.4% |
| FY2022 | 2022-12-31 | (25.8M) | -12.4% |
| FY2021 | 2021-12-31 | (22.95M) | — |
Free Cash Flow vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's LTM Mar 2026 free cash flow of $38.97M is the 4th largest of the 11 companies compared; the peer median is $26.99M.
- Its year-over-year change of +44.5% is the 2nd highest of 10, against a peer median of -10.5%.
- Free cash flow amounts to 206.5% of revenue for PROF, versus a peer median of 68.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $107.32M | +3.5% | +96.9% | 17365.9% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $86.69M | +25.6% | +36.9% | 4683.3% |
| LTM Dec 2025 | $47.63M | +21.0% | -3.8% | 365.8% | |
| LTM Mar 2026 | $38.97M | +44.5% | +14.8% | 206.5% | |
| LTM Mar 2026 | $34.14M | — | — | 30.0% | |
| LTM Mar 2026 | $29.51M | -10.5% | +2.8% | 91.4% | |
| LTM Mar 2026 | $24.47M | -32.5% | -8.8% | 827.3% | |
| LTM Mar 2026 | $20.3M | -42.8% | -17.0% | 45.2% | |
| LTM Mar 2026 | $13.58M | -63.6% | -14.6% | 9.0% | |
| LTM Mar 2026 | $12.24M | +202.4% | -0.1% | 21.2% | |
| LTM Mar 2026 | $11.16M | -23.6% | -48.9% | 10.4% | |
| Peer median (excluding PROF) | $26.99M | -10.5% | -3.8% | 68.3% | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.7M) | (28.67M) | (28.32M) | (27.82M) | (42.57M) |
| Depreciation & Amortization | 1.88M | 1.6M | 929K | 936K | 569.8K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.21M | 4.24M | 3.42M | 2.58M | 5.49M |
| Change in Working Capital | (877K) | (5.63M) | 540K | 591K | (1.74M) |
| Accounts Receivables | 2M | (1.42M) | (956K) | 186K | (175.01K) |
| Inventory | (2.49M) | (1.86M) | 353K | 656K | (2.87M) |
| Accounts Payables | (356K) | (566K) | 1.35M | 815K | 384.62K |
| Other Working Capital | (26K) | (1.78M) | (211K) | (1.07M) | 918.81K |
| Other Non-Cash Items | 132K | 2.66M | 828K | 255K | (622.65K) |
| Operating Cash Flow | (22.36M) | (25.8M) | (22.61M) | (23.45M) | (38.88M) |
| Capital Expenditures | (593K) | 0 | 0 | 0 | (179.08K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (561K) | 0 | 0 | 0 | 91.63K |
| Investing Cash Flow | (593K) | 0 | 0 | 0 | (246.24K) |
| Debt Repayment | (386K) | 6.92M | (912K) | (2.56M) | (1.33M) |
| Common Stock Issued | 0 | 0 | 0 | 62.11M | 43.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.33M | 114K | 2.67M | (4.85M) | 0 |
| Financing Cash Flow | 5.95M | 7.03M | 1.76M | 54.7M | 41.86M |
| Effect of Forex Changes | 244K | (1.87M) | 549K | (2.54M) | 2M |
| Net Change in Cash | (16.76M) | (20.64M) | (20.3M) | 28.7M | 4.73M |
| Free Cash Flow | (22.95M) | (25.8M) | (22.61M) | (23.45M) | (39.05M) |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.